Here we report the results of a phase IIa pilot study, performed in RA patients, who previously experienced a secondary failure of anti-TNF biologics
Here we report the results of a phase IIa pilot study, performed in RA patients, who previously experienced a secondary failure of anti-TNF biologics. 90 (n = 6), 180 (n = 12), or 360 g TNF-K (n = 12). The primary objective was to identify the best dose and schedule based on anti-TNF antibody titers.… Read More: Here we report the results of a phase IIa pilot… »